Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MRNA |
---|---|---|
09:32 ET | 64536 | 151.71 |
09:34 ET | 8690 | 151.05 |
09:36 ET | 19860 | 151.835 |
09:38 ET | 11381 | 152.07 |
09:39 ET | 14305 | 152.515 |
09:41 ET | 7612 | 151.5301 |
09:43 ET | 5507 | 152.48 |
09:45 ET | 10395 | 151.8 |
09:48 ET | 4290 | 151.58 |
09:50 ET | 7483 | 151.82 |
09:52 ET | 11169 | 152.195 |
09:54 ET | 5426 | 151.59 |
09:56 ET | 8373 | 151.16 |
09:57 ET | 12580 | 151.735 |
09:59 ET | 5155 | 151.64 |
10:01 ET | 8325 | 151.71 |
10:03 ET | 7744 | 152.14 |
10:06 ET | 6196 | 152.56 |
10:08 ET | 21677 | 150.865 |
10:10 ET | 24681 | 150.27 |
10:12 ET | 13332 | 151.34 |
10:14 ET | 11328 | 150.84 |
10:15 ET | 19320 | 151.3 |
10:17 ET | 14707 | 151 |
10:19 ET | 3815 | 150.9931 |
10:21 ET | 2007 | 150.87 |
10:24 ET | 13886 | 150.13 |
10:26 ET | 27070 | 150.07 |
10:28 ET | 8405 | 150.67 |
10:30 ET | 5193 | 150.985 |
10:32 ET | 466 | 151.04 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Moderna Inc | 54.6B | -9.6x | --- |
ICON PLC | 26.9B | 38.1x | +4.68% |
Biogen Inc | 32.8B | 28.5x | -18.14% |
Biontech SE | 23.9B | 195.5x | --- |
Grifols SA | 6.2B | 74.8x | --- |
Charles River Laboratories International Inc | 10.7B | 25.5x | +15.57% |
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $54.6B |
---|---|
Revenue (TTM) | $5.2B |
Shares Outstanding | 383.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-15.66 |
Book Value | $36.27 |
P/E Ratio | -9.6x |
Price/Sales (TTM) | 10.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -99.73% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.